Abstract: A method for analyzing concentration of a cardiovascular disease (CVD) biomarker in a liquid sample includes: applying the liquid sample to a biosensor, the biosensor including a transistor having a drain, a source, and a gate terminal disposed between the gate and the source, and a reactive electrode spaced apart from the gate terminal of the transistor and having a receptor immobilized thereon for specific binding with the CVD biomarker, the liquid sample being in contact with the gate terminal and the reactive electrode; applying a voltage pulse between the reactive electrode and the source, the voltage pulse having a pulse width; monitoring a response current in response to the voltage pulse; and analyzing the response current.

Abstract: A method for analyzing concentration of a cardiovascular disease (CVD) biomarker in a liquid sample includes: applying the liquid sample to a biosensor, the biosensor including a transistor having a drain, a source, and a gate terminal disposed between the gate and the source, and a reactive electrode spaced apart from the gate terminal of the transistor and having a receptor immobilized thereon for specific binding with the CVD biomarker, the liquid sample being in contact with the gate terminal and the reactive electrode; applying a voltage pulse between the reactive electrode and the source, the voltage pulse having a pulse width; monitoring a response current in response to the voltage pulse; and analyzing the response current.

Abstract: The present invention provides a Hemoglobin A1c-specific aptamer and a Hemoglobin-specific aptamer. The aptamers were selected in vitro using SELEX and a microfluidic chip system. The aptamers established low free energy, thus were more stable than conventional antibodies. The high specificity of the aptamers to Hemoglobin A1c or Hemoglobin allows them to be effectively used in diagnosis of diabetes and/or anemia.

Abstract: The present invention provides a Hemoglobin A1c-specific aptamer and a Hemoglobin-specific aptamer. The aptamers were selected in vitro using SELEX and a microfluidic chip system. The aptamers established low free energy, thus were more stable than conventional antibodies. The high specificity of the aptamers to Hemoglobin A1c or Hemoglobin allows them to be effectively used in diagnosis of diabetes and/or anemia.

Abstract: An aptamer specifically binding to C-reactive protein (CRP) is provided. The aptamer includes a following nucleotide sequence: 5?-angngggngnntgnnt-3?, wherein n is a nucleotide selected from a, t, c and g.

Abstract: The present invention provides a microfluidic chip device for selecting a cell aptamer. The microfluidic chip device comprising a plurality of storage reservoirs; a fluid control unit; a reaction tank; and a PCR reaction tank, wherein each storage reservoir interconnects with the fluid control unit, and via a corresponding pumping/mixing element, the sample and the reagent are mixed and then transported into each storage reservoir. The present invention further provides a method for selecting a cell aptamer.

Abstract: An aptamer specifically binding to C-reactive protein (CRP) is provided. The aptamer includes a following nucleotide sequence: 5?-angngggngnntgnnt-3?, wherein n is a nucleotide selected from a, t, c and g.